

Depreotide

Cat. No.:	HY-114133
CAS No.:	161982-62-3
Molecular Formula:	C ₆₅ H ₉₆ N ₁₆ O ₁₂ S ₂
Molecular Weight:	1357.69
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Depreotide is a novel tumor tracer, can be complexed with technetium-99m (^{99m} Tc-depreotide) for optimal imaging properties. ^{99m} Tc-depreotide somatostatin receptor imaging has been playing an important role in medical diagnosis research ^[1] .
In Vitro	Depreotide, complexed with technetium-99m to form (99m)Tc-depreotide, binds somatostatin receptors (SSTRs) with high affinity to SSTRs 2, 3, and 5 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	^{99m} Tc-depreotide (sodium chloride 0.9% w/v solution; i.v.; single dose) shows an optimal image interpretation with SPECT images (Single Photon Emission Computed Tomography) between 2 and 4 hours following injection ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Rodrigues M, et al. ^{99m}Tc-depreotide scintigraphy versus ¹⁸F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab. 2006 Oct;91(10):3997-4000.

[2]. Halley A, et al. Efficiency of ¹⁸F-FDG and ^{99m}Tc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1026-32.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA